Summary

New generation drug-eluting stents (DESs) are increasingly efficient and safe, while the ABSORB everolimus-eluting bioresorbable vascular scaffold (BVS) is thought to reduce long-term complications, including neoatherosclerosis and very late stent thrombosis. The objective of the Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stent trial [EVERBIO II; NCT01711931] was to compare the efficacy of the BVS with the best-in-class new generation DESs.